🟢 Lantern Pharma is trading 7.91% up today in pre-market after USPTO allows LP-284 blood-cancer patent

Lantern Pharma is trading at $1.50, up 7.91%, after the USPTO issued a Notice of Allowance for its LP-284 blood-cancer treatment patent.

• Allowed claims cover mantle-cell and double-hit lymphomas, potentially extending patent protection into 2042.
• The company also hosted an Open-Medicine AI webinar on September 23; biotech sentiment is supportive.